Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer

[1]  NCCN Guidelines® Updates: Gastric Cancer , 2022, Journal of the National Comprehensive Cancer Network.

[2]  A. Jager,et al.  Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial , 2022, Clinical Drug Investigation.

[3]  A. Jager,et al.  Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer , 2021, Clinical Pharmacokinetics.

[4]  A. Witteveen,et al.  Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial. , 2021 .

[5]  Carin A Uyl-de Groot,et al.  Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare. , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  E. Winer,et al.  Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. V. van't Veer,et al.  Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. , 2020, European journal of cancer.

[8]  M. Louwman,et al.  Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007–2017 , 2020, Acta dermato-venereologica.

[9]  S. Michiels,et al.  Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  W. V. van Harten,et al.  Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms , 2019, Breast Cancer Research and Treatment.

[11]  M M Regan,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Postma,et al.  PCN393 - THE BURDEN OF INFORMAL CARE FOR BREAST CANCER PATIENTS IN THE NETHERLANDS , 2018, Value in Health.

[14]  J. Cuzick,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  I. Vaz-Luis,et al.  Managing side effects in adjuvant endocrine therapy for breast cancer , 2018, Expert review of anticancer therapy.

[16]  E. Winer,et al.  Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer , 2018, The New England journal of medicine.

[17]  M. Postma,et al.  Burden of early, advanced and metastatic breast cancer in The Netherlands , 2018, BMC Cancer.

[18]  G. Vilagut,et al.  Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries , 2018, The European Journal of Health Economics.

[19]  S. Dewilde,et al.  What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life? , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  L. Esserman,et al.  Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades , 2017, JAMA oncology.

[21]  I. Frayling,et al.  Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. , 2017, Health technology assessment.

[22]  M. Postma,et al.  Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands , 2017, Journal of medical economics.

[23]  I. Jacobs,et al.  Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) , 2016, PLoS ONE.

[24]  W. Brouwer,et al.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare , 2016, PharmacoEconomics.

[25]  G Ardine de Wit,et al.  Dutch Tariff for the Five-Level Version of EQ-5D. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  Todd C. Skaar,et al.  Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer , 2016, The oncologist.

[27]  F. Lötters,et al.  Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements , 2016, Calcified Tissue International.

[28]  P. Vemer,et al.  AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users , 2015, PharmacoEconomics.

[29]  M. Koopmanschap,et al.  The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  R. J. Baatenburg de Jong,et al.  Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands , 2015, European Archives of Oto-Rhino-Laryngology.

[31]  J. Cuzick,et al.  Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial , 2015, The Lancet. Oncology.

[32]  Philip W. Kantoff,et al.  Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer , 2013, Annals of Internal Medicine.

[33]  W. Lynch,et al.  Direct and Indirect Costs of Women Diagnosed With Menopause Symptoms , 2013, Journal of occupational and environmental medicine.

[34]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[35]  P. van Baal,et al.  Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations , 2011, PharmacoEconomics.

[36]  Hein Putter,et al.  Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial , 2011, The Lancet.

[37]  Michael Hauptmann,et al.  Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. , 2010, European journal of cancer.

[38]  Ron M. C. Herings,et al.  Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis , 2010, Breast Cancer Research and Treatment.

[39]  B. Jönsson,et al.  Health related quality of life in different states of breast cancer , 2007, Quality of Life Research.

[40]  P. Romundstad,et al.  Incidence and mortality of venous thrombosis: a population‐based study , 2007, Journal of thrombosis and haemostasis : JTH.

[41]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[42]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[43]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[44]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[45]  K. Cowan,et al.  Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. , 2020, Ontario health technology assessment series.